Prevention strategies for Alzheimer's disease

Translational Neurodegeneration

Volumn 1, Issue , 2012, Pages

  Gauthier, Serge ^a   Wu, Liyong ^b   Rosa Neto, Pedro ^a   Jia, Jianping ^b  

^a MCGILL UNIVERSITY   (Canada)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer disease; Clinical practice; Clinical trial; Prevention; Risk factor

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; OMEGA 3 FATTY ACID;

ALZHEIMER DISEASE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DEMENTIA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FAMILY HISTORY; GENDER; HUMAN; LIFESTYLE MODIFICATION; MENTAL DETERIORATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 84877883111     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-1-13     Document Type: Review

References (31)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031. 10.1016/S0140-6736(10)61349-9, 21371747.
2. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010, 9:702-716. 10.1016/S1474-4422(10)70119-8, 20610346.
3. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & dementia : the journal of the Alzheimer's Association 2008, 4:156-163. 3423412, 22916152.
4. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002, 137:149-155.
5. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006, 5:735-741. 10.1016/S1474-4422(06)70537-3, 16914401.
6. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699. 10.1016/0140-6736(93)91705-Q, 8103819.
7. Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr 2008, 20:1-16.
8. Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?. J Nutr Health Aging 2007, 11:338-341.
9. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128. 10.1016/S1474-4422(09)70299-6, 2819840, 20083042.
10. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011, 7:280-292. 3423412, 22916152.
11. Thal LJ. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20(Suppl 2):S97-S99.
12. Feldman HH, Jacova C. Primary prevention and delay of onset of AD/dementia. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2007, 34(Suppl 1):S84-S89.
13. Touchon J, Portet F, Gauthier S. Prevention trials in Alzheimer disease: one step forward?. Neurology 2006, 67(Suppl 3):S21-S22.
14. Green RC, DeKosky ST. Primary prevention trials in Alzheimer disease. Neurology 2006, 67(Suppl 3):S2-S5.
15. Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, et al. Methodological issues in primary prevention trials for neurodegenerative dementia. Journal of Alzheimer's disease : JAD 2009, 16:235-270. 3423412, 22916152.
16. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's research & therapy 2011, 3:1. 3423412, 22916152.
17. Loewenstein DA, Greig MT, Schinka JA, et al. An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers Dement 2012, 8:172-179. 10.1016/j.jalz.2011.03.002, 22546351.
18. Carrie I, Abellan Van Kan G, Gilette-Guyonnet S, et al. Recruitment strategies for preventive trials: the MAPT Study (Multidomain Alzheimer Preventive Trial). J Nutrition Health Aging 2012, 16:355-359.
19. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351. 10.1016/S0140-6736(98)03086-4, 9802273.
20. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008, 7:683-689. 10.1016/S1474-4422(08)70143-1, 18614402.
21. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's disease and cognitive decline. Evidence Report/Technical Assessment no 193 2010,
22. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 2011, 95:594-600. 10.1016/j.pneurobio.2011.08.014, 21925234.
23. Wu L, Rosa-Neto P, Gauthier S. Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Mol Diagn Ther 2011, 15:313-325. 10.1007/BF03256467, 22188635.
24. Thal LJ. Potential prevention strategies for Alzheimer disease. Alzheimer Dis Assoc Disord 1996, 10(Suppl 1):6-8.
25. Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One 2012, submitted.
26. Fredrickson J, Maruff P, Woodward M, Moore L, Fredrickson A, Sach J, et al. Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology 2010, 34:65-75. 10.1159/000264823, 20016215.
27. Snyder PJ, Jackson CE, Petersen RC, et al. Assessment of cognition in mild cognitive impairment: a comparative study. Alzheimers Dement 2011, 7:338-355. 10.1016/j.jalz.2011.03.009, 21575877.
28. Darby DG, Brodtmann A, Pietrzak RH, Fredrickson J, Woodward M, Villemagne VL, et al. Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. Journal of Alzheimer's disease : JAD 2011, 27:627-637. 3423412, 22916152.
29. Andrieu S, Ousset PJ, Coley N, Ouzid M, Mathiex-Fortunet H, Vellas B. GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. 1. rationale, design and baseline data. Curr Alzheimer Res 2008, 5:406-415. 10.2174/156720508785132271, 18690838.
30. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262. 10.1001/jama.2008.683, 2823569, 19017911.
31. Yaffe K, Tocco M, Petersen RC, et al. The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials. Alzheimers Dement 2012, 8:237-242. 10.1016/j.jalz.2011.12.005, 22546356.